(0.78%) 5 057.48 points
(0.68%) 38 160 points
(1.37%) 15 820 points
(0.03%) $79.02
(5.43%) $2.04
(0.08%) $2 312.80
(0.44%) $26.87
(0.76%) $962.20
(-0.06%) $0.932
(-0.28%) $11.00
(-0.08%) $0.798
(-1.33%) $92.02
Live Chart Being Loaded With Signals
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States...
Stats | |
---|---|
Šios dienos apimtis | 1.13M |
Vidutinė apimtis | 2.41M |
Rinkos kapitalizacija | 26.49B |
EPS | HKD0 ( 2023-10-30 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -9.93 |
ATR14 | HKD0.0940 (0.31%) |
Tūris Koreliacija
REMEGEN-B Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
REMEGEN-B Koreliacija - Valiuta/Žaliavos
REMEGEN-B Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD1.08B |
Bruto pelnas: | HKD822.99M (76.48 %) |
EPS: | HKD-2.80 |
FY | 2023 |
Pajamos: | HKD1.08B |
Bruto pelnas: | HKD822.99M (76.48 %) |
EPS: | HKD-2.80 |
FY | 2022 |
Pajamos: | HKD767.78M |
Bruto pelnas: | HKD497.84M (64.84 %) |
EPS: | HKD-1.880 |
FY | 2021 |
Pajamos: | HKD1.42B |
Bruto pelnas: | HKD1.36B (95.28 %) |
EPS: | HKD0.680 |
Financial Reports:
No articles found.
REMEGEN-B
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.